美金刚联合多巴丝肼对帕金森病痴呆预后效果、安全性分析

目的：探究美金刚联合多巴丝肼对帕金森病痴呆预后效果、安全性分析。方法：选择2018年1月-12月某院收治的帕金森痴呆患者200例，按照随机数字表法分为参照组与研究组，各100例。参照组行多巴丝肼治疗，研究组在参照组基础上加用美金刚。治疗结束后对比2组患者的日常生活能力、智力、认知能力、血清免疫指标、不良反应。结果：治疗结束后，研究组（39.16±4.24）患者日常生活能力评分显著高于参照组（34.56±4.67）（t=4.382 8，P=0.041 7）。停药后2个月，研究组（39.68±3.76）患者日常生活能力评分显著高于参照组（34.31±3.45）（t=4.168 4，P=0.040 3）。对认知能力评分，停药后研究组患者评分（13.89±2.41）显著高于参照组（11.76±2.54）（t=4.785 7，P=0.048 5），停药2个月后，研究组（13.56±2.37）显著高于参照组（11.87±2.42）（t=5.765 6，P=0.047 3）。同样，IgG水平、IgM水平，研究组均改善优于参照组，具有显著差异（P<0.05）。对比2组患者停药后不良反应，研究组不良反应发生率低于参照组具有显著性差异（P<0.05）。结论：对帕金森患者实施美金刚联合多巴丝肼治疗，有效改善痴呆症状，不良反应少，安全性高，治疗效果显著。

Effect and safety of memantine combined with dopa and serazide on prognosis of dementia in patients with Parkinson's disease

OBJECTIVE To investigate the effect and safety of memantine combined with dopa serazide on prognosis of Parkinson's disease dementia.METHODS 200 patients with Parkinson's dementia who were treated in our hospital from January 20 to 2018 were enrolled in the study. According to the random number table method, they were divided into reference group and study group, with 100 cases in each group. The reference group was treated with dopa and serazide, and memantine was added to the reference group in the study group. After treatment, the activities of daily living, intelligence, cognitive ability, serum immune index and adverse reactions were compared between the two groups.RESULTS After the end of treatment, patients in the study group (39.16±4.24) had significantly higher scores of activities of daily living than those in the reference group (34.56±4.67) (t=4.382 8, P=0.041 7).Two months after discontinuation, patients in the study group (39.68±3.76) had significantly higher scores in activities of daily living than those in the reference group (34.31±3.45) (t=4.168 4, P=0.040 3). The scores of cognitive ability were significantly higher in the study group (13.89±2.41) than in the reference group (11.76±2.54) (t=4.785 7, P=0.048 5) after drug withdrawal, and significantly higher in the study group (13.56±2.37) than in the reference group (11.87±2.42) (t=5.765 6, P=0.047 3) after 2 months of drug withdrawal. Similarly, With regard to IgG levels, IgM levels, all indicators were better in the study group than those in the reference group, and the difference was significant (P<0.05). The incidence of adverse reactions in the study group was significantly lower than that in the reference group (P<0.05).CONCLUSION The treatment of Parkinson's patients with memantine combined with dopasine is effective in improving the symptoms of dementia, with less adverse reactions, high safety and significant therapeutic effect.